Modified CHO Cell Line for Stable MVA Vaccine Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing production of Modified Vaccinia Virus Ankara (MVA) relies on laborious and time-consuming primary chicken embryo fibroblast cells, which are prone to contamination, making them unsuitable for efficient and stable vaccine production, especially on an industrial scale.
Innovation Solution
Genetically modify Chinese hamster ovary (CHO) cells to express poxvirus host range genes CP77, K1L, and optionally SPI-1, enabling these cells to support MVA replication and overcome the host range restriction of MVA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary chicken embryo fibroblast cells are used for MVA production, then MVA replication is supported, but the process becomes laborious, time-consuming, and prone to contamination
Solution Approach 1:
The patent changes the cell type parameter from primary chicken embryo fibroblasts to genetically modified Chinese hamster ovary cells. This parameter change enables industrial-scale production while maintaining MVA replication capability, thereby reducing production time and improving stability without compromising viral yield
Solution Approach 2:
The patent creates a cell line copy (CHO cells) that replicates the functional capability of primary CEF cells for MVA production but with improved characteristics. The modified CHO cells serve as a stable surrogate system that can be continuously cultured, eliminating the need for repeated primary cell isolation and reducing contamination risks
2Productivity
If primary chicken embryo fibroblast cells are used for MVA production, then MVA replication is supported, but contamination risk increases and scalability is limited
Solution Approach 1:
The patent uses genetically modified CHO cells as a stable cell line copy that maintains MVA replication support while eliminating the contamination and scalability issues of primary cells. This cell line copy can be continuously cultured in controlled industrial environments, significantly reducing contamination risk
Solution Approach 2:
The patent employs a disposable cell line system that can be easily discarded and replaced if contaminated, unlike valuable primary cells. The engineered CHO cells serve as a consumable substrate that can be continuously produced and replaced, reducing the impact of contamination on overall production
3Reliability
If MVA is used with its natural host range restriction, then safety is maintained, but replication in mammalian cells is limited
Solution Approach 1:
The patent segments the host range limitation by introducing specific host range genes (CP77, K1L, SPI-1) as separate functional modules into the MVA system. This allows the virus to adapt to mammalian cells while maintaining its attenuated safety profile, effectively decoupling safety from host range restriction
Solution Approach 2:
The patent uses expressed host range genes as intermediary factors that mediate between MVA and mammalian cells. These genes (CP77, K1L, SPI-1) act as bridges that enable replication in mammalian systems without altering the core safety characteristics of the attenuated virus
Data Source
AI summary
The present invention relates to a mammalian non-human cell line, specifically Chinese hamster ovary (CHO) cells, that is genetically modified to express poxvirus host range genes CP77, K1L and/or SPI-1 which are not expressed in MVA, and to the use of said cell line in the reproduction of MVA.